Sulfhydryl oxidase (Shd) inhibitors represent a chemical class of compounds designed to specifically target and modulate the activity of the sulfhydryl oxidase enzyme. Sulfhydryl oxidases are a group of enzymes that play a pivotal role in catalyzing the oxidation of thiol (sulfhydryl) groups to disulfide bonds in proteins. This enzymatic process is essential for maintaining protein structure and function, as disulfide bonds contribute to the stabilization of protein tertiary and quaternary structures. By inhibiting the activity of Shd enzymes, Shd inhibitors can interfere with the formation of disulfide bonds, potentially impacting various biological processes and cellular functions where these bonds are crucial.
Shd inhibitors can be synthesized through chemical design and structural modifications to enhance their specificity and efficacy in targeting Shd enzymes. These inhibitors typically possess molecular moieties or functional groups that interact with key catalytic residues of Shd enzymes, disrupting their ability to facilitate thiol oxidation. As a consequence, the formation of disulfide bonds in proteins may be hindered or altered, affecting the structure and function of various proteins within cells and tissues. The study of Shd inhibitors is of great significance in elucidating the role of disulfide bonds in cellular processes, redox regulation, and protein folding. Researchers are continually exploring the development and utilization of Shd inhibitors to gain insights into these fundamental biological mechanisms.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib inhibits the epidermal growth factor receptor (EGFR), a tyrosine kinase that can influence SHB activity through its downstream signaling. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib targets the BCR-ABL kinase and other tyrosine kinases, potentially altering SHB-mediated signaling pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a kinase involved in cell growth and proliferation, potentially affecting pathways where SHB is involved. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that could reduce AKT phosphorylation and activity, impacting signaling pathways associated with SHB. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple tyrosine kinases, which may indirectly influence SHB signaling by modifying RTK-mediated pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor, possibly affecting various signaling cascades including those involving SHB. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib inhibits multiple receptor tyrosine kinases, potentially altering SHB signaling pathways. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an Src family kinase inhibitor, which could influence SHB function due to Src's role in tyrosine kinase signaling. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which could impact SHB signaling through the ERK pathway. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits JNK, potentially affecting AP-1 transcription factor activity and thereby modulating SHB-related pathways. | ||||||